Literature DB >> 8494364

Efficacy of prophylaxis with beta-lactams and beta-lactam-beta-lactamase inhibitor combinations against wound infection by methicillin-resistant and borderline-susceptible Staphylococcus aureus in a guinea pig model.

D S Kernodle1, A B Kaiser.   

Abstract

Although some beta-lactams and beta-lactam-beta-lactamase inhibitor combinations exhibit activity against methicillin-resistant Staphylococcus aureus, there remains the concern that therapeutic failures may result from the selection of resistant subpopulations. The prophylactic use of these antibiotics in clean surgery, however, may prove adequate since wound infections arise from the inoculation of small numbers of bacteria. In this clinical setting, heterogeneity in the phenotypic expression of beta-lactam resistance may facilitate antibiotic efficacy. Similarly, beta-lactamase-mediated resistance in S. aureus is dependent on inoculum size, and it may be possible to prevent infection from small inocula with relatively labile beta-lactams. To test this hypothesis, antibiotics were administered to guinea pigs as prophylaxis against infection by two methicillin-resistant strains and one borderline-susceptible strain. Following prophylaxis with sulbactam or placebo, inoculation of only a dozen or fewer bacteria had a 50% probability of creating an abscess (50% infective dose [ID50]). The efficacy of ampicillin was similar to that of cefazolin, exhibiting moderate activity against the borderline-susceptible strain (ID50s, greater than 300 bacteria) and minimal activity against the methicillin-resistant strains (ID50s, fewer than 100 bacteria). Coadministration of sulbactam with ampicillin or cefazolin yielded better results than the beta-lactam alone for five of six strain-beta-lactam combinations, including an 80-fold increase in the efficacy of ampicillin-sulbactam compared with that of ampicillin for one methicillin-resistant strain (ID50s, 2,017 and 25 bacteria, respectively). Prophylaxis with beta-lactams, especially beta-lactam-beta-lactamase inhibitor combinations, reduces the risk of wound infection by beta-lactam-resistant S. aureus.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8494364      PMCID: PMC187738          DOI: 10.1128/AAC.37.4.702

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  32 in total

1.  The virulence of Staphylococcus pyogenes for man; a study of the problems of wound infection.

Authors:  S D ELEK; P E CONEN
Journal:  Br J Exp Pathol       Date:  1957-12

2.  Methicillin-resistant Staphylococcus aureus infections of sternal wounds.

Authors:  A Perceval
Journal:  Infect Control Hosp Epidemiol       Date:  1992-03       Impact factor: 3.254

3.  Production of low-affinity penicillin-binding protein by low- and high-resistance groups of methicillin-resistant Staphylococcus aureus.

Authors:  K Murakami; K Nomura; M Doi; T Yoshida
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

Review 4.  Methicillin-resistant staphylococci.

Authors:  H F Chambers
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

Review 5.  The beta-lactamases of gram-negative bacteria and their role in resistance to beta-lactam antibiotics.

Authors:  R B Sykes; M Matthew
Journal:  J Antimicrob Chemother       Date:  1976-06       Impact factor: 5.790

6.  In vitro bactericidal activity of sulbactam plus ampicillin against methicillin-resistant Staphylococcus aureus.

Authors:  A Kazmierczak; J M Duez; A Pechinot; P Nordmann; R Labia
Journal:  Rev Infect Dis       Date:  1986 Nov-Dec

Review 7.  Pharmacokinetics of sulbactam/ampicillin in humans: a review.

Authors:  G Foulds
Journal:  Rev Infect Dis       Date:  1986 Nov-Dec

8.  Outline of details for official microbiological assays of antibiotics.

Authors:  A Kirshbaum; B Arret
Journal:  J Pharm Sci       Date:  1967-04       Impact factor: 3.534

9.  Characterization of a widespread strain of methicillin-susceptible Staphylococcus aureus associated with nosocomial infections.

Authors:  L W McMurray; D S Kernodle; N L Barg
Journal:  J Infect Dis       Date:  1990-09       Impact factor: 5.226

10.  Borderline susceptibility to antistaphylococcal penicillins is not conferred exclusively by the hyperproduction of beta-lactamase.

Authors:  N Barg; H Chambers; D Kernodle
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

View more
  6 in total

1.  Ampicillin-sulbactam is effective in prevention and therapy of experimental endocarditis caused by beta-lactamase-producing coagulase-negative staphylococci.

Authors:  M C Ramos; M Ing; E Kim; M D Witt; A S Bayer
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

2.  Synergism between poly-(1-6)-beta-D-glucopyranosyl-(1-3)-beta-D-glucopyranose glucan and cefazolin in prophylaxis of staphylococcal wound infection in a guinea pig model.

Authors:  A B Kaiser; D S Kernodle
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

3.  Prophylactic anti-infective activity of poly-[1-6]-beta-D-glucopyranosyl-[1-3]-beta-D-glucopryanose glucan in a guinea pig model of staphylococcal wound infection.

Authors:  D S Kernodle; H Gates; A B Kaiser
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

4.  Impact of methicillin-resistant Staphylococcus aureus prevalence among S. aureus isolates on surgical site infection risk after coronary artery bypass surgery.

Authors:  Loren G Miller; James A McKinnell; Michael E Vollmer; Brad Spellberg
Journal:  Infect Control Hosp Epidemiol       Date:  2011-04       Impact factor: 3.254

5.  Comparative prophylactic efficacies of ciprofloxacin, ofloxacin, cefazolin, and vancomycin in experimental model of staphylococcal wound infection.

Authors:  D S Kernodle; A B Kaiser
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

Review 6.  The guinea pig as a model of infectious diseases.

Authors:  Danielle J Padilla-Carlin; David N McMurray; Anthony J Hickey
Journal:  Comp Med       Date:  2008-08       Impact factor: 0.982

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.